Latest Breaking News On - Jean mathieu beauregard - Page 1 : comparemela.com

13.05.2022 - POINT s manufacturing facility initiated supply for the Phase 3 SPLASH trial. Randomization of patients for the SPLASH trial expanded to the European Union as scheduled. CTA filed with Health Canada for Phase 1 therapeutic trial for PNT6555, the .

United statesUnited kingdomJean mathieu beauregardJoe mccannDaniel pearlsteinBiopharma global incDevelopment expensesWinter american college of nuclear medicineEuropean unionHealth canadaSociety of nuclear medicineUs department of energy isotope programCompany indianapolisNuclear medicineMolecular imagingAmerican college